Nurix Therapeutics Inc [NASDAQ: NRIX] loss -3.87% or -0.51 points to close at $12.67 with a heavy trading volume of 4403661 shares.
It opened the trading session at $14.48, the shares rose to $14.5604 and dropped to $12.09, the range by which the price of stock traded the whole day. The daily chart for NRIX points out that the company has recorded -34.08% loss over the past six months.
If we look at the average trading volume of 856.15K shares, NRIX reached to a volume of 4403661 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Nurix Therapeutics Inc [NRIX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NRIX shares is $30.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NRIX stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Nurix Therapeutics Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on March 17, 2025. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on December 10, 2024, representing the official price target for Nurix Therapeutics Inc stock. Previously, the target price had yet another raise to $35, while BMO Capital Markets analysts kept a Outperform rating on NRIX stock.
The Price to Book ratio for the last quarter was 2.16, with the Price to Cash per share for the same quarter was set at 6.37.
Trading performance analysis for NRIX stock
Nurix Therapeutics Inc [NRIX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.85. With this latest performance, NRIX shares gained by 1.04% in over the last four-week period, additionally sinking by -34.08% over the last 6 months – not to mention a drop of -32.75% in the past year of trading.
Nurix Therapeutics Inc [NRIX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Nurix Therapeutics Inc [NRIX] shares currently have an operating margin of -260.75% and a Gross Margin at 80.00%. Nurix Therapeutics Inc’s Net Margin is presently recorded at -234.58%.
Return on Equity for this stock declined to -37.61%, with Return on Assets sitting at -37.61%.
Nurix Therapeutics Inc [NRIX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NRIX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nurix Therapeutics Inc go to -5.24%.
An analysis of Institutional ownership at Nurix Therapeutics Inc [NRIX]
There are presently around $111.85%, or 113.45% of NRIX stock, in the hands of institutional investors. The top three institutional holders of NRIX stocks are: BLACKROCK INC. with ownership of 6.82 million shares, which is approximately 10.9334%. REDMILE GROUP, LLC, holding 4.42 million shares of the stock with an approximate value of $$92.32 million in NRIX stocks shares; and REDMILE GROUP, LLC, currently with $$83.3 million in NRIX stock with ownership which is approximately 6.3989%.
